Madelyn Wiegand, MD
Endocrinology, Diabetes & Metabolism · Slidell, LANPI 1740281708
Payments from drug & device makers
Across 687 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$870
- Amgen$824
- Novo Nordisk$719
- Sanofi-aventis U.S. LLC$708
- Boehringer Ingelheim$636
- plus $6K from 35 others
What the payments were for
- Food & beverage$10,698100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 93 | $1,442 |
| AbbVie | 58 | $870 |
| Amgen | 60 | $824 |
| Novo Nordisk | 44 | $719 |
| Sanofi-aventis U.S. LLC | 48 | $708 |
| Boehringer Ingelheim | 42 | $636 |
| Amneal Pharmaceuticals LLC | 40 | $590 |
| IBSA Pharma Inc. | 36 | $578 |
| Bayer | 33 | $564 |
| Abbott | 33 | $556 |
| AstraZeneca(2 entities) | 28 | $424 |
| Dexcom, Inc. | 20 | $421 |
| Xeris Pharmaceuticals, Inc. | 21 | $357 |
| Lifescan, Inc. | 22 | $276 |
| Kowa Pharmaceuticals America, Inc. | 13 | $226 |
| Corcept Therapeutics | 14 | $217 |
| BETA Bionics, Inc. | 10 | $199 |
| Amarin Pharma, Inc. | 11 | $164 |
| Merck | 12 | $158 |
| Insulet Corporation | 5 | $98 |
| Tandem Diabetes Care, Inc. | 5 | $84 |
| Ascendis Pharma Endocrinology Inc | 4 | $77 |
| Medtronic(2 entities) | 5 | $65 |
| BD | 4 | $55 |
| Sequel Med Tech, LLC | 3 | $52 |
| Madrigal Pharmaceuticals | 2 | $37 |
| Shire North American Group Inc | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Embecta Corp. | 2 | $28 |
| Radius Health, Inc. | 2 | $28 |
| Alfasigma USA, Inc. | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Pfizer | 2 | $27 |
| Rhythm Pharmaceuticals, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $14 |
| Medicure Pharma Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,730 in reported general payments places this provider in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 267 | $343,648 |
| TrulicityDulaglutide | 151 | $210,097 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 184 | $191,647 |
| FarxigaDapagliflozin Propanediol | 206 | $166,782 |
| JardianceEmpagliflozin | 172 | $163,859 |
| OzempicSemaglutide | 126 | $144,317 |
| RybelsusSemaglutide | 34 | $71,087 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $70,072 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 50 | $53,027 |
| SynthroidLevothyroxine Sodium | 583 | $45,719 |
| FiaspInsulin Aspart (Niacinamide) | 31 | $37,602 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $36,768 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $33,218 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $29,917 |
| KerendiaFinerenone | 22 | $26,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,442 | $556,661431 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi | $636 | $371,832376 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $719 | $258,005208 claims |
| AstraZenecaFarxiga | $424 | $166,782206 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $708 | $56,50470 claims |
| AbbVieSynthroid | $870 | $45,719583 claims |
| BayerKerendia | $564 | $26,17322 claims |
| AmgenProlia | $824 | $20,75912 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $590 | $18,848738 claims |
| PfizerLevoxyl | $27 | $7,557159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Slidell
- Ileana TandronSlidell$527K
- Tuan Huy TranMetairie$2M
- Harold MillerHammond$1.1M
- Timothy GilbertBaton Rouge$985K
- Justin FontenotLafayette$905K
- Vivian FonsecaNew Orleans$700K
- Frank GreenwayBaton Rouge$669K
- Abdul KhanHammond$587K
- Jonathan WiseMetairie$463K
- Marideli ScanlanMarrero$446K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.